Velafermin (CuraGen).
CuraGen is developing velafermin (CG-53135), human fibroblast growth factor-20 administered intravenously, for the potential treatment and prevention of oral mucositis (OM). By December 2004, phase II trials for the prevention of OM in cancer patients undergoing bone marrow transplant had been initiated, and in September 2005 CuraGen indicated that results from this study will be reported during the first quarter of 2006.
Lalla
Rajesh V
RV
Department of Oral Health and Diagnostic Sciences MC1605, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030-1605, USA. lalla@nso2.uchc.edu
D000818:Animals; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D005346:Fibroblast Growth Factors / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007262:Infusions, Intravenous; D010330:Patents as Topic; D011837:Radiation-Protective Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D011878:Radiotherapy / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic; D013280:Stomatitis / Q000188:drug therapy* / Q000209:etiology
C416003:FGF20 protein, human; D011837:Radiation-Protective Agents; D005346:Fibroblast Growth Factors